Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: mchip who wrote (5230)	8/15/1998 10:09:00 AM
From: Bradpalm1	Read Replies (2) \| Respond to of 7041

<<I did not think Viagra's problem was with nitrates specifically. but that nitrates are used in most high blood pressure medicine>> This statement is factually incorrect. Viagra's problem IS specifically with nitrates and nitrates are NOT in most high blood pressure medicines. Another factor about Vasomax' Phase III trial results that is overlooked is the patient exclusion criteria they used (thanks to Dr. Goldstein). Patients ultimately enrolled in these studies were pre-screened to avoid any adverse effects to Vasomax. Further, the drop-out rate was unusually high (mostly due to lack of a therapeutic response). FDA review committees usually reject NDAs containing such skewed information. Bradpalm1